Abstract: Objective To analyze the expression and clinical significance of serum soluble intercellular adhesion molecule-1(sICAM-1) and galectin-3 in patients with chronic heart failure. Methods A total of 452 patients of with chronic heart failure admitted to Chun'an Branch of the First People's Hospital of Hangzhou from March 2016 to March 2019 were divided into NYHA Ⅱ group(151 cases), NYHA Ⅲ group(164 cases), and NYHA Ⅳ group(137 cases) according to NYHA classification. According to the occurrence of major adverse cardiovascular events(MACE) during the follow-up period, the patients were divided into MACE group and non-MACE group, another 73 cases of physical examination in our hospital during the same period were selected as the control group. The serum levels of sICAM-1 and galectin-3 were measured. Results The expression levels of sICAM-1 in the chronic heart failure group was(771.08±186.54) μg/L and galectin-3 was(21.26±4.35) ng/mL, there were significantly higher than those in the control group(all P<0.05). The expression levels of sICAM-1 and galectin-3 in the NYHA grade Ⅳ and NYHA grade Ⅲ groups were significantly higher than those in the NYHA grade Ⅱ group(all P<0.05), and that in the NYHA grade Ⅳ group was significantly higher than that in the NYHA grade Ⅲ group(P<0.05). The expression levels of sICAM-1 and galectin-3 in the MACE group on the next day of admission and the day of discharge were significantly higher than those of the non-MACE group(P<0.05). The expression of sICAM-1 and Galectin-3 on the day of discharge in the non-MACE group was significantly lower than that on the day after admission(P<0.05). There was a significant positive correlation between sICAM-1 and galectin-3 in patients with chronic heart failure(r=0.671, P=0.004). Conclusion The expression of sICAM-1 and galectin-3 in serum is related to the cardiac function and prognosis in patients with chronic heart failure.